Using AI to predict molecular pathology in glioma from histopathology images
Histopathology Images Based Prediction of Molecular Pathology in Glioma Using Deep Learning or Machine Learning
This study is trying to see if artificial intelligence can help predict the specific types of gliomas using images of the tumors to improve treatment options for patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Ages | 1 Year to 95 Years |
| Sex | All |
| Sponsor | The First Affiliated Hospital of Zhengzhou University Academic / other |
| Locations | 1 site (Zhengzhou, Henan) |
| Trial ID | NCT04217044 on ClinicalTrials.gov |
What this trial studies
This observational registry collects clinical, molecular, and radiologic data from patients with primary gliomas, including detailed clinical parameters and histopathology images. By utilizing artificial intelligence, the study aims to develop algorithms that can accurately predict molecular pathology and subgroups of gliomas based on these images. The registry will include over 1000 samples to enhance the precision and non-invasive nature of molecular predictions, ultimately aiding in personalized treatment approaches for glioma patients.
Who should consider this trial
Good fit: Ideal candidates are patients with a confirmed diagnosis of primary glioma who are scheduled for tumor resection and have a life expectancy of more than three months.
Not a fit: Patients without gliomas, insufficient tumor tissue for molecular detection, or those with severe systemic malfunctions may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate and personalized treatment options for glioma patients based on their molecular pathology.
How similar studies have performed: Other studies utilizing artificial intelligence for histopathology image analysis have shown promising results, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients must have radiologically and histologically confirmed diagnosis of primary glioma * Life expectancy of greater than 3 months * Must receive tumor resection * Signed informed consent Exclusion Criteria: * No gliomas * No sufficient amount of tumor tissues for detection of molecular pathology * Patients who are pregnant or breast feeding * Patients who are suffered from severe systematic malfunctions
Where this trial is running
Zhengzhou, Henan
- Department of Neurosurgery, First Affiliated Hospital of Zhengzhou University — Zhengzhou, Henan, China (Recruiting)
Study contacts
- Study coordinator: Zhenyu Zhang, Dr.
- Email: fcczhangzy1@zzu.edu.cn
- Phone: +86 17839973727
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.